262 related articles for article (PubMed ID: 25145809)
1. The effects of epistaxis on health-related quality of life in patients with hereditary hemorrhagic telangiectasia.
Merlo CA; Yin LX; Hoag JB; Mitchell SE; Reh DD
Int Forum Allergy Rhinol; 2014 Nov; 4(11):921-5. PubMed ID: 25145809
[TBL] [Abstract][Full Text] [Related]
2. The minimal important difference of the epistaxis severity score in hereditary hemorrhagic telangiectasia.
Yin LX; Reh DD; Hoag JB; Mitchell SE; Mathai SC; Robinson GM; Merlo CA
Laryngoscope; 2016 May; 126(5):1029-32. PubMed ID: 26393959
[TBL] [Abstract][Full Text] [Related]
3. Validation of epistaxis severity score for hereditary hemorrhagic telangiectasia in Japan.
Hayama M; Maeda Y; Shikina T; Tatehara S; Inokuchi G; Hoag JB; Sato T; Obata S; Nakatani A; Amano Y; Hida E; Nibu KI; Inohara H
Auris Nasus Larynx; 2022 Jun; 49(3):415-420. PubMed ID: 34857410
[TBL] [Abstract][Full Text] [Related]
4. A new endoscopic staging system for hereditary hemorrhagic telangiectasia.
Reh DD; Yin LX; Laaeq K; Merlo CA
Int Forum Allergy Rhinol; 2014 Aug; 4(8):635-9. PubMed ID: 24782401
[TBL] [Abstract][Full Text] [Related]
5. Quality of life in patients with hereditary haemorrhagic telangiectasia (HHT).
Zarrabeitia R; Fariñas-Álvarez C; Santibáñez M; Señaris B; Fontalba A; Botella LM; Parra JA
Health Qual Life Outcomes; 2017 Jan; 15(1):19. PubMed ID: 28114930
[TBL] [Abstract][Full Text] [Related]
6. Management of epistaxis in hereditary hemorrhagic telangiectasia by Nd:YAG laser and quality of life assessment using the HR-QoL questionnaire.
Karapantzos I; Tsimpiris N; Goulis DG; Van Hoecke H; Van Cauwenberge P; Danielides V
Eur Arch Otorhinolaryngol; 2005 Oct; 262(10):830-3. PubMed ID: 15739086
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life in hereditary hemorrhagic telangiectasia.
Geisthoff UW; Heckmann K; D'Amelio R; Grünewald S; Knöbber D; Falkai P; König J
Otolaryngol Head Neck Surg; 2007 May; 136(5):726-33; discussion 734-5. PubMed ID: 17478205
[TBL] [Abstract][Full Text] [Related]
8. Altered quality of life in Rendu-Osler-Weber disease related to recurrent epistaxis.
Ingrand I; Ingrand P; Gilbert-Dussardier B; Defossez G; Jouhet V; Migeot V; Dufour X; Klossek JM
Rhinology; 2011 Jun; 49(2):155-62. PubMed ID: 21743869
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life in a rare disease: hereditary hemorrhagic telangiectasia (HHT) or Rendu-Osler-Weber disease.
Pasculli G; Resta F; Guastamacchia E; Di Gennaro L; Suppressa P; Sabbà C
Qual Life Res; 2004 Dec; 13(10):1715-23. PubMed ID: 15651542
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Timolol in a Novel Intranasal Thermosensitive Gel for Hereditary Hemorrhagic Telangiectasia-Associated Epistaxis: A Randomized Clinical Trial.
Peterson AM; Lee JJ; Kallogjeri D; Schneider JS; Chakinala MM; Piccirillo JF
JAMA Otolaryngol Head Neck Surg; 2020 Nov; 146(11):1006-1014. PubMed ID: 32940653
[TBL] [Abstract][Full Text] [Related]
11. Development and performance of a hereditary hemorrhagic telangiectasia-specific quality-of-life instrument.
Kasthuri RS; Chaturvedi S; Thomas S; Vandergrift N; Bann C; Schaefer N; Clancy MS; Pyeritz R; McCrae KR
Blood Adv; 2022 Jul; 6(14):4301-4309. PubMed ID: 35877137
[TBL] [Abstract][Full Text] [Related]
12. Integration of clinical parameters, genotype and epistaxis severity score to guide treatment for hereditary hemorrhagic telangiectasia associated bleeding.
Beckman JD; Li Q; Hester ST; Leitner O; Smith KL; Kasthuri RS
Orphanet J Rare Dis; 2020 Jul; 15(1):185. PubMed ID: 32660636
[TBL] [Abstract][Full Text] [Related]
13. The natural history of epistaxis in patients with hereditary hemorrhagic telangiectasia in the Norwegian population: a cross-sectional study.
Dheyauldeen S; Abdelnoor M; Bachmann-Harildstad G
Am J Rhinol Allergy; 2011; 25(4):214-8. PubMed ID: 21819756
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide for the Management of Bleeding Episodes in Patients with Hereditary Hemorrhagic Telangiectasia: Effects on Epistaxis Severity Score and Quality of Life.
Baysal M; Ümit EG; Kırkızlar HO; Özdöver AC; Demir AM
Turk J Haematol; 2019 Feb; 36(1):43-47. PubMed ID: 29880465
[TBL] [Abstract][Full Text] [Related]
15. Correlation of severity of epistaxis with nasal telangiectasias in hereditary hemorrhagic telangiectasia (HHT) patients.
Pagella F; Colombo A; Matti E; Giourgos G; Tinelli C; Olivieri C; Danesino C
Am J Rhinol Allergy; 2009; 23(1):52-8. PubMed ID: 19379613
[TBL] [Abstract][Full Text] [Related]
16. Intranasal Efudix reduces epistaxis in hereditary hemorrhagic telangiectasia.
de Jel DVC; Disch FJM; Kroon S; Mager JJ; Verdam FJ
Angiogenesis; 2020 Aug; 23(3):271-274. PubMed ID: 32112177
[TBL] [Abstract][Full Text] [Related]
17. Intranasal bevacizumab injections improve quality of life in HHT patients.
Steineger J; Geirdal AØ; Osnes T; Heimdal KR; Dheyauldeen S
Laryngoscope; 2020 May; 130(5):E284-E288. PubMed ID: 31287573
[TBL] [Abstract][Full Text] [Related]
18. Complications from office sclerotherapy for epistaxis due to hereditary hemorrhagic telangiectasia (HHT or Osler-Weber-Rendu).
Hanks JE; Hunter D; Goding GS; Boyer HC
Int Forum Allergy Rhinol; 2014 May; 4(5):422-7. PubMed ID: 24431220
[TBL] [Abstract][Full Text] [Related]
19. Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial.
Whitehead KJ; Sautter NB; McWilliams JP; Chakinala MM; Merlo CA; Johnson MH; James M; Everett EM; Clancy MS; Faughnan ME; Oh SP; Olitsky SE; Pyeritz RE; Gossage JR
JAMA; 2016 Sep; 316(9):943-51. PubMed ID: 27599329
[TBL] [Abstract][Full Text] [Related]
20. Assessing the Psychometric Validity of the Epistaxis Severity Score: Internal Consistency and Test-Retest Reliability.
Gong AJ; Bolsegui ML; Lee EE; Mathai SC; Weiss CR
Am J Rhinol Allergy; 2024 Jan; 38(1):38-46. PubMed ID: 37822162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
